This saves patients hours annually, time they can spend with family, at work, or relaxing, while also offering major ...

Although anti-PD-1 therapy, alone or in combination with an anti-CTLA-4 agent, has become the first-line standard of care for ...

England's National Health Service will soon offer nivolumab as a quick injection for cancer patients. This new method cuts ...

Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier® ...

Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...

The complete remission of a testicular cancer patient receiving Mink Therapeutics Inc.’s allogeneic, off-the-shelf invariant natural killer T-cell therapy Agent-797 with nivolumab drove the company’s ...

Most patients with advanced melanoma treated with pre-surgical immunotherapy remained alive and free of disease four years post-treatment.

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer ...

Modified Herpes Virus as a Weapon Against Skin Cancer? A new study suggests it might work—even for metastases deep within the ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...